Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: HMG-CoA reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the â€œstatinâ€ class of cholesterol-lowering drugs. Mevastatin is a HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. It inhibits HMG-CoA reductase in a reversible and competitive manner with a Ki value of 1 nM for the open ring acid form of the molecule. During a 24 week study period, a dose of 30 mg/day mevastatin reduced plasma LDL-cholesterol approximately 29% in patients with familial hypercholesterolemia. Mevastatin also suppresses TNF-induced NF- kappa B activation (IC50 = ~17 µM), which potentiates apoptosis in human myeloid leukemia cells and thus, may be useful in treating cancer.
Mevastatin is supplied as a crystalline solid. A stock solution may be made by dissolving the mevastatin in an organic solvent purged with an inert gas. Mevastatin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of mevastatin in these solvents is approximately 5 mg/ml. Mevastatin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, mevastatin should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Mevastatin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery 2, 517-526 (2003).
Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569-1582 (1992).
Ahn, K.S., Sethi, G., and Aggarwal, B.B. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kB pathway. Biochem. Pharmacol. 75, 907-913 (2008).